We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Decelerated vesting

22 Mar 2004 By Hugo Dixon

The payment to Richard Sykes to postpone the accelerated vesting of options when he merged Glaxo and SmithKline was unfortunate. But there’s poetic justice. After the deal, the shares plummeted, meaning his decelerated options expired worthless.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)